Moderna's Covid vaccine candidate boasts of 94.5% efficacy rate

• DMSB had undertaken the Phase-3, COVE study for Moderna’s mRNA vaccine 
• The vaccine gave a 94.5% efficacy rate.
• EMA to start a ‘rolling review’ of data on mRNA-1273 based on clinical trial results 

THD NewsDesk, London: Moderna’s revolutionary mRNA Covid vaccine has successfully cleared the Phase-3 study trials conducted by the Data Safety Monitoring Board with an efficacy rate of 94.5%. Earlier, the National Institute of Health, an independent body, had appointed DSMB for undertaking the clinical trials of Moderna’s vaccine candidate, mRNA-1273. 

DMSB has informed NIH that the trial was conducted according to the study protocol’s specified statistical criteria. 

Known as the COVE study, the trial was conducted on over 30,000 participants from the US in partnership with the NIAID and BARDA. The National Institute of Allergy and Infectious Diseases is a part of the NIH. Simultaneously, the Biomedical Advanced Research and Development Authority (BARDA) belongs to the US Department of Health and Human Services.

Further, the European Medicine Agency’s (EMA) Human Medicines Committee has announced that it would soon publish a ‘rolling review’ of data on the vaccine. The thought would be based on the preliminary results from non-clinical studies and early clinical studies. The studies indicate that the vaccine effectively simulates the production of antibodies and immunity T cells that can destroy the virus.

Source: Express Healthcare